New antimicrobial agents for the treatment of Gram-positive bacterial infections

Creative Commons License

AKSOY D. Y., ÜNAL S.

CLINICAL MICROBIOLOGY AND INFECTION, vol.14, no.5, pp.411-420, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 14 Issue: 5
  • Publication Date: 2008
  • Doi Number: 10.1111/j.1469-0691.2007.01933.x
  • Journal Name: CLINICAL MICROBIOLOGY AND INFECTION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.411-420
  • Keywords: ceftobiprole, daptomycin, linezolid, quinupristin-dalfopristin, review, tigecycline, RESISTANT STAPHYLOCOCCUS-AUREUS, SKIN-STRUCTURE INFECTIONS, IN-VITRO ACTIVITY, COMPLICATED INTRAABDOMINAL INFECTIONS, BROAD-SPECTRUM CEPHALOSPORIN, AORTIC-VALVE ENDOCARDITIS, SOFT-TISSUE INFECTIONS, METHICILLIN-RESISTANT, ENTEROCOCCUS-FAECIUM, VANCOMYCIN-INTERMEDIATE
  • Hacettepe University Affiliated: Yes

Abstract

Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylococci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the treatment of resistant infections. Linezolid, quinupristin-dalfopristin, daptomycin, tigecyline, new glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development. This review summarises their major properties, the results of recent studies with these agents, and future treatment possibilities.